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Five methods are compared to estimate the total area .under the digoxin plasma or serum 
concentration-time curve (A UC 0-oo) after a single dose of drug. To obtain accurate estimates of 
A UC 0-oo, data required are concentrations at a sufficient number of sampling times to define 
adequately the concentration-time curve prior to the log-linear phase, and at least three, but 
preferably four or more equally spaced points in the terminal log-linear phase. One method 
(designated Method I) requires a digital computer; another (Method III) is the classical method 
(these two methods do not require equally spaced points in the log-linear phase). Method IIA is the 
accelerated convergence method of Amidon et al.; Methods IIB and l lC  are modifications of this 
method, but incorporate usual and orthogonal least squares, respectively, which make them more 
accurate with real (noisy) data. Methods I and l lC  gave very comparable estimates of A UC O-oo. 
Results indicate that digoxin administered orally in aqueous solution was completely (100%) 
absorbed when bioavailability estimates were based on oral and intravenous A UC 0--oo estimates 
and the actual doses, whereas formerly only about 80% absorption was reported, based on areas, 
under plasma concentration curves which were truncated at 96 hr. It is shown that the sampling 
scheme of blood can produce biased apparent bioavailability estimates when areas under 
truncated curves are employed, but an appropriate sampling scheme and application of method 
IIC yield accurate bioavailability estimates. This is important particularly in those bioavailability 
studies where one is attempting to determine the appropriate label dose for a new "fast-release" 
digoxin preparation relative to the label dose and bioavailability of currently marketed tablets. It is 
shown that the magnitudes and variability of apparent elimination rate constants and half-lives of 
digoxin, estimated ffom urinary excretion data by the tr- method, depend on which value of A~ ~ is 
used. The formerly reported greater interindividual variability of A UC data compared to Ar data 
for digoxin is explained in that the A UCs, but not the A~'s, involve the renal clearance, which 
exhibits considerable inter- and intraindividual variation. 
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INTRODUCTION 
Pharmacokinetic equations appropriate to estimation of absolute or 
relative bioavailability (used here with the connotation of absorption 
efficiency only, without the other component of rate of absorption) involve 
ratios of dose-corrected total areas under plasma or serum concentration- 
time curves (AUC 0-~),  or total amounts of unchanged drug excreted in the 
urine in infinite time (A~) after a single dose of drug (la,2). The word 
"total" herein refers to AUC 0-oo or A ~ and not, as often erroneously used 
in the literature, to indicate AUC 0-T or Aft, where T is the investigator's 
last sampling time; hence AUC 0-T is a partial area and AT is a partial 
amount excreted in the urine. In this article, such partial areas and amounts 
excreted are simply designated by AUC'and Ae, respectively. 
It is common practice in the digoxin (7-21), as well as the literature for 
many other drugs, to substitute the particular author's AUC or Ae figures 
for AUC 0-co or A e ~ in estimating bioavailability. Such estimates are herein 
called apparent bioavailabilities. For digoxin there have been almost as many 
blood sampling schemes as investigators. Apparent bioavailabili.ties depend 
on the sampling scheme employed, and they may be considerable underesti- 
mates of the true bioavailability. This will be very important in establishing 
the correct dose ratio of new "fast-release" digoxin formulations compared 
with currently marketed "slow-release" tablets, since an error of the order 
of 20% could have noticeable effects in the clinical use of digoxin. The 
shortcomings of reporting such apparent bioavailabilities have been pointed 
out before by other authors (4,6,16,24). We could find only one article (16) 
where estimates of A ~  for digoxin had been made, but the method was not 
given. No article could be found where AUC 0-oo had been estimated for 
digoxin after oral administration. Several authors (3,7,9,10,12,14-16,19- 
21) have collected either 0-6 or 0-10 day digoxin urinary excretion data in 
those cases when they were employing a radioimmunoassay method for 
digoxin in plasma or serum which had a sensitivity level of 0.2-0.5 ng/ml 
and which allowed them to follow digoxin in blood only for about 8 hr. 
However, as assay has been in the literature (22) since 1972 which allows 
measurement of digoxin down to 0.08 ng/ml of plasma or serum, and for 
96 hr after a single 0.5-mg dose of digoxin (5). This assay has been improved 
(23) and has a sensitivity limit of 0.05 ng digoxin/ml plasma when a 0.5-ml 
plasma sample is utilized. The authors have used this improved assay in 
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several digoxin bioavailability studies where blood was sampled over a 96-hr 
period. 
The articles of Wagner et al. (2,5) and Lovering et al. (17) suggested that 
apparent bioavailabilities estimated from partial areas may be close to the 
true bioavailabilities under certain conditions. In a recent review on digoxin 
(18) it was stated: "However, if blood sampling is continued for an interval 
(T) after the dose which is sufficient to allow serum concentrations to 
become quite small, then AUC 0-T is a good approximation of AUC 0-oo." 
It was (18) further stated: "In our studies of comparative bioavailability, 4 hr 
of serum sampling gave results as reliable as 8 or 24 hr of sampling." The 
same authors (15) also stated: "Extending urine collections beyond 1 day or 
serum sampling beyond 4 or 8 hr does not necessarily reduce between 
subject variability or enhance the usefulness of the data." However, 
Beveridge et al. (16) stated: "Therefore, statements on bioavailabitity [of 
digoxin] based on areas under plasma curves up to 6 hr may differ from those 
based on cumulative urinary excretion'data, in this case by a factor of about 2 
[i.e., a 100% error] and could suggest that bioavailability was much worse 
than it actually was." This dichotomy of opinion prompted us to examine, in 
general, the assessment of bioavailability and, in particular, to study digoxin 
bioavailability. In the process, several new simple methods for estimating 
AUC 0-oo and A ~ were devised and applied. 
THEORETICAL 
Methods for Estimating AUC 0 - ~  and A ~  
All known methods and the new methods to be presented for estima- 
tion of AUC 0-oo and A ~  depend on accurate estimates of AUC or Ae at 
various times after administration of a single dose of drug. For AUC the 
trapezoidal rule (lb) is usually employed, and with sufficient sampling times 
(see rows 6, 7, and 8 of Table III) is accurate for digoxin. An even more 
accurate method would be that resulting from interpolation by the method 
of Fried and Zeitz (25), which has been computerized (lc), coupled with the 
trapezoidal rule using both observed and interpolated values. All methods 
(I, IIA, liB, IIC, and III) discussed below are applicable only to AUC or Ae 
data in the terminal, log-linear phase. Methods IIA, B, and C below also 
depend on having three or more blood or urine collections at equally spaced 
time intervals in the terminal log-linear phase of drug elimination; for 
accurate results, it is later shown that four such collections is the minimum 
necessary. The classical method (Method III) for estimating AUC 0-oo also 
depends on an accurate estimate of the apparent elimination rate constant, 
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which also requires at least three and preferably four or more plasma 
concentration-time points (i.e., Cp, t pairs). 
Method I 
Method I depends on nonlinear least-squares fitting to equation 1 of log 
linear AUC, t or Ae, t data using a suitable program and a digital computer: 
y = P(1) - P ( 3 )  e-P(2)' (1) 
For AUC data, y represents AUC at time t, P(1) represents AUC 0-w,  P(2) 
represents h 1, and P(3) represents B1/~, 1, such that the plasma concentra- 
tion, Cp, in the log-linear phase is described by equation 2. The B1 in 
equation 2 (and later equation 13) is ~i complex function of model para- 
meters: 
Cp = B 1 e-~ 1, (2) 
For Ae data, y represents Ae at time t, P(1) represents A~ ,  P(2) 
represents )tl, and P(3) is equivalent to C1RB1, where CIR is the renal 
clearance. 
To apply the method, we used the program NONLIN (26) and the 
Amdahl 470V/6 digital computer. P(1), P(2), and P(3) are the parameters 
estimated in the fittings. The method has two advantages: (a) the points may 
be equally or nonequally spaced and (b) one obtains the standard deviations 
of the estimated AUC 0 - ~  or A e ~ as well as measures of fit of predicted 
AUC or Ae to observed AUC or Ae values. 
Method I IA  
Method IIA is the accelerated convergence method of Amidon et al. 
(27). For a series of points, (ti, Y~), approaching an asymptote, Y~, and 
obeying first-order kinetics from time t', the general equation 3 applies, 
where A 1 is the first-order rate constant: 
Yi = Yoo[1-e -A'('-c)] (3) 
For three equally spaced points, at intervals, At, particular cases of equation 
3 may be written as 
Y1 = Voo[1-e -x'a'] (4) 
Y2 = Yoo[1-e -2x~a'] (5) 
Y3 = Yoo[1-e -3a~at] (6) 
Amidon et al. (27) used different symbolism such that Y1 = their X,, 
Y2 = their X,+I, I"3 = their X,+z, and Y~ = their X ' .  They also plotted the 
differences on the ordinate but ended up deriving the expression corres- 
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ponding to these differences being plotted on the abscissa. Hence we prefer 
to plot the differences on the abscissa in order to apply Methods l ib  and IIC 
discussed later. 
Consider a rectalinear plot of Y =  Y~ (ordinate) vs. X =  Y~+I-Y~ 
(abscissa) with the equation of the straight line being Y = a + bX; two points 
on the line are ( Y 2 -  Y1), Y2 and (II3 - Y2), Y3; the line extrapolates back to 
give an ordinate intercept, a, equal to Yoo; the slope of the line, b, is given by 
equation 7, and the slope is negative since YI < Y2 < Y3 and (Y2-  Ya) > 
(II3-- Y2). 
(Y2-  Y3) 113- Y2 
b ( y 2 _ y 1 ) _ ( y 3 _ Y 2 )  = Y a - 2 Y E + Y ~  (7) 
When Y = II3, the equation of the line is given by 
y3 = yoo+[ Y 3 -  Y2 ] (8) Y 3 - 2 Y 2 +  YI (Y3-  Y2) = Yooq (Y3-  I"2) 2 
Y3-  2Y2 + Y1 
Rearrangement of equation 8 gives equation 9, which is equivalent to 
the equation given by Amidon et al. (27): 
(Y3-  Y2) 2 
Yoo = I13 (9) 
Y 3 - 2 Y 2 +  Y1 
The validity of equation 9 with respect to first-order kinetics is readily 
checked by substituting for Y1, I"2, and Y3 in equation 9 from equations 4 
through 6 and showing that the right-hand side is equal to the left-hand side, 
As a simulation for AUC data after bolus intravenous administration of 
digoxin, let the values of the parameters of equation 1 be P(1)=  44.67, 
P(2) = 0.0122, and P(3) = 37.44. Substitution of these values and t = 24, 48, 
and 72 hr into equation 1 yielded the values below. 
t Y, 
24 16.73 = Y1 
48 23.82 =Y2 
72 29.12=I"3 
Substitution of the above values into equation 9 and simplification gave 
Yoo = 44.81. The actual value of P(1) = Yoo = AUC 0-oo = 44.67, while the 
estimated value by this method is 44.81. Hence with these error-free data 
the method gave an answer with an error of +0.45%. 
Method IIB 
Method IIB is a modification of Method IIA, but three or more points 
may be utilized (see Fig. 3 as an example). Equation 10 is a generalization of 
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equation 8: 
Y/= Yoo-(slope)(Y~+l- Y/) (10) 
Equation 10 indicates that a plot of Y~ vs .  (Y /+I  - Y/)  will have an ordinate 
intercept equal to Yoo and a negative slope, when the method of least squares 
is applied to the data and first-order kinetics is obeyed. To illustrate the 
method, the data used to illustrate Method IIA were extended by adding a 
I"4 value for 96 hr and these data are shown below: 
t Y = Y~ X = Y~+I- Y~ 
24 16.73= Y1- - .~7 .09  
48 23.82 = Y i ~  5.30 
72 29.12= Y3~.._y4 > 3 " 9 4  
96 33.06 = 
Using ordinary least-squares linear regression and the pairs of values 
X = 7 . 0 9  and Y=16.73, X=5.30 ,  and Y=23.82, and X=3 .94  and 
Y = 29.12, equation 11 was obtained with a correlation coefficient of 1.000. 
The intercept, 44.64, is 
Y = 44.64-  3.935X (11) 
the estimate of AUC 0 - ~  and is within -0.07% of the actual value of 44.67. 
Methods IIA and liB give the same answer when there are only three Y~ 
values and the line is based on only two points. 
Method I IC 
Method IIC is the same as Method liB, with the exception that 
orthogonal least squares (28) is used in place of ordinary least squares. In 
applying both methods, trapezoidal areas should not be rounded off before 
calculating the parameters of the least-squares line, but final intercept values 
should be rounded off to the same number of places as the original blood 
level or urinary excretion data. The equations used to obtain the slope and 
intercept of the orthogonal least-squares line are shown in the Appendix. 
With the same data as used to illustrate Method liB, Method IIC gave the 
same intercept, 44.64, with an error of -0.07%. However, with other data 
sets orthogonal least squares and ordinary least squares do not give the same 
answer. Since both YI and Y~+I - Y~ contain errors, orthogonal least squares 
is preferred from a statistical point of view. Hence Method IIC is preferred 
to Method liB. 
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Method III 
Method II is the classical method (la)  for estimating AUC 0 - ~  using 
AUC 0-c~ = trapezoidal area 0 - T +  Cr/A 1 (12) 
In equation 12, T is the last sampling time in the log-linear phase and 
(~T is the estimated concentration at that time obtained with equation 14. 
The value of h l is obtained by least-squares regression based on equation 
13. 
In Cp = In B1 - h  it (13) 
d T : e (lnBl-xlT) (14) 
As indicated formerly, one should have a minimum of three and preferably 
four or more Cp, t or Ae,t pairs in the log-linear phase and adequate sampling 
in the early time period with blood data to apply equation 12. 
Other Methods 
When the Guggenheim method (ld,29) was applied to the data which 
were used to illustrate Methods liB and IIC, the AUC 0-oo estimate was 
37.50, with a large error of -16.1%. When the "rate method" (le) was 
applied to the same data, the AUC 0-az estimate was 37'.64, with a large 
error of -15.3 %. Since these two methods gave such large errors even with 
"error-free" data, they were not considered further for application to 
digoxin AUC,t data. The Results and Discussion section indicates that the 
same conclusion was reached with respect to digoxin urinary excretion data. 
Variability of AUC and Ae Data 
There have been several reports (9,15,18) that interindividual AUC 
data are more variable than interindividual Ae data, and the conclusion was 
reached that Ae data provide a more reliable estimate of apparent bioavaila- 
bility than AUC data. There is a simple pharmacokinetic explanation for 
such differences in variability. AUC data are influenced by an additional 
variable, namely renal clearance, Cln, which does not influence Ae data. If 
the system obeys linear pharmacokinetics, then equations 15-17 apply: 
Ae = Cln 9 AUC (15) 
Ae ~ = fFF*D (16) 
AUC 0-00 = fFF*D/CIn (17) 
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In equations 16 and 17, f is the fraction of the drug which reaches the 
circulation which is excreted in the urine, F is the bioavailability factor 
concerned with incomplete absorption ( 0 -  F-< 1), F* is the bioavailability 
factor concerned with the "first-pass effect" (0 < -F*-  < 1), and D is the dose 
administered orally. For the intravenous route, F = 1 and the same equa- 
tions apply. F* has meaning only when both oral and intravenous data are 
considered together. 
Koup et al. (14) reported renal clearances of digoxin in eight subjects 
following both bolus intravenous injections and intravenous infusions. 
Interindividual coefficients of variation of the C1R values were 40.8% and 
37.8% for bolus and infusion, respectively. Intrasubject variability of CIR is 
reflected by the coefficient of variation calculated from the differences in the 
pairs of CIR values for the eight subjects; this coefficient of variation was 
43.8%. This suggests that intraindividual variation and interindividual 
variation of the C1R of digoxin are very similar. Similar calculations made by 
the authors from CIR data collected in two recent digoxin bioavailability 
studies, one involving 12 and the other involving 15 subjects, also gave little 
differences between inter- and intraindividual variation of C1R. Thus one can 
readily see with such an additional variable (CIR) being "contained in" AUC 
data, but not in Ae data, why AUC data are more variable than Ae data. 
Equations for both AUC and Ae will be analogous to equations 16 and 17, 
but will also ~contain exponential terms; those equations for data in the 
log-linear phase will contain a term with e -~1' (like equation 1); those for 
data in the postabsorptive, distribution phase will contain two terms, one 
with e -~1' and one with e -x2'. Therefore, on a theoretical basis one would 
expect AUC to a given time to be more variable than AUC 0-oo, and Ae to a 
given time to be more variable than A e ~. 
Estimation o| AUC 0 - ~  from Data ot Wagner et al. (5) 
Wagner et al. (5) reported digoxin plasma concentration-time data for 
two subjects administered labeled doses of 0.5 mg of digoxin by 1-hr 
constant-rate intravenous infusion, as a solution orally, as two B & W 
tablets, and as two Fougera tablets (both 0.25 mg/tablet) orally. The blood 
sampling scheme employed is shown in the sixth row of Table III. For each 
subject and each treatment, AUC 0-oo was estimated by Methods I, IIA, 
IIB, IIC, and III. The needed AUC,t data were obtained by application of 
the trapezoidal rule (lb) to each set of Cp,t data. Bioavailability estimates, 
based on ratios of dose-corrected AUC 0-oo's, were compared with appar- 
ent bioavailabilities, calculated from dose-corrected AUCs at various times 
after administration, using the 1-hr intravenous infusion data as the "stan- 
dard" in both cases. 
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Importance of Blood Sampling Scheme 
Digoxin plasma concentration-time data were simulated for a "fast- 
release" (A) and a "slow-release" (B) digoxin formulation. Equations used 
are shown in the Appendix. The advantage of such a procedure is that the 
exact answers are known against which "experimental answers" may be 
compared. Eight different blood sampling schemes were compared: six of 
these were taken from the literature; a seventh scheme was used by the 
authors in a recent unpublished study; the eighth scheme led to the points 
shown in Fig. 2. The equations used to generate these data were chosen so 
that the simulated plasma concentrations from 3 hr to infinity were identical 
to the third decimal place for A and B. This provided a minimum (not a 
maximum) test to show the effect of the blood sampling scheme on apparent 
bioavailabilities. It also provided a means to show that the reasoning of 
Lovering et al. (17) is faulty, when applied to digoxin. 
Estimation of A ~  from Data of Juhl et  al.  (20) 
The individual subject/treatment sets of A~,t data of Juhl et al. (20) 
were employed to obtain estimates of A~ ~ by Methods I, IIA, IIB, and IIC. 
Ae S, were compared with Bioavailability estimates, based on ratios of the ~ 
apparent bioavailabilities, based on ratios of Ae's to various times. Appar- 
ent elimination rate constants, A 1, were calculated, using the method of least 
squares, the different A~  estimates, and equation 18, in which In I is the 
intercept and its value depends on the particular model which applies. 
In ( A ~ - A e )  = In l -A~ t  (18) 
RESULTS A ND DISCUSSION 
Estimation of AUC 0-oo from Data of Wagner et aL (5) 
The averages of duplicate assay values reported by Wagner et al. (5) 
were used as the Cv,t data. The AUCs were obtained by trapezoidal rule. 
AUCs in the log-linear phase, corresponding to 24, 48, 72, and 96 hr for oral 
treatments and 25, 49, 73, and 97 hr for the 1 hr constant-rate intravenous 
infusion, were employed to estimate AUC 0-oo values, which are shown in 
Table I. Plotting of data according to equation 10 (see Fig. 3 for example 
with urinary excretion data) indicated that elimination was not apparent first 
order at 12 hr, but was at 24 hr, when plasma data were evaluated. Data for 
the Fougera tablet in subject 2 were anomalous in that the data did not obey 
apparent first-order kinetics (see footnotes to Table I). For the other seven 
sets of data, the AUC 0 -o ' s  estimated by Method IIC agreed extremely well 
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Table I. Summary of AUC 0--oo for Digoxin Estimated from the Plasma Concentration-Time 
Data of Wagner et al. (5) 
AUC 0-o0 [(ng/mi) x hr] 
1 hr i.v. Solution B & W tablet Fougera tablet 
Subject Method infusion orally orally orally 
I 43.2 ~ 40.1 a 20.1 a 9.03 a 
(0.82) b (3.42) (0.08) (0.20) 
IIA 41.5 c 51.2 ~ 20.3 c 9.50 c 
IIB 43.1 a 39.2 a 20.1 a 9.00 a 
IIC 43.2 a 39.3 ~ 20.1 ~ 9.02 ~ 
III 44.8 a 37.6 a 20.0 a 8.53 ~ 
I 44.7 ~ 42.0 ~ 21.7 a 15.2 ~ 
(4.97) (0.02) (1.06) (8.56) 
IIA 37.3 c 42.1 c 24.9 c e 
liB 42.8 ~ 42.0 ~ 21.5 ~ .e 
IIC 44.3 ~ 42.0 ~ 21.7 ~ e 
III 47.5 ~ 49. I a 20.2 a 23.4 ~ 
'*Four partial areas to 25, 49, 73, and 97 hr were used for the intravenous data and those to 24, 
48, 72, and 96 hr were used for the oral data. 
bNurnbers in parentheses are standard deviations of the estimated areas. 
CThree partial areas to 25, 49, and 73 hr were used for the intravenous data and those to 24, 48, 
and 72 hr were used for the oral data. 
dThree partial areas to 48, 72, and 96 hr were used. 
eMethods gave ridiculous answers, indicating that data were not obeying first-order kinetics; 
this was also indicated by the very large standard deviation of 8.56 for an estimated area of 
15.2 by Method I and the discrepancy of the answers obtained by Methods I and III. 
with the A U C  0-o0's  es t imated  by Me thod  I, the m e a n  absolute  devia t ion  
be ing  0.17 (ng /ml )  x hr (0.5% of m e a n  by Me thod  I), and  in four  out  of the 
seven sets the es t imates  were identical .  For  Methods  I and  IIB the m e a n  
absolu te  dev ia t ion  was 0.45 (ng /ml )  • hr  (0.7% of m e a n  by Me thod  I), for 
Methods  I and  I I I  it was 2.3 (ng /ml )  x hr (7.3% of m e a n  by Method  I), and  
for Methods  I and  I I A  it was 3.45 (ng /ml)  • hr  (11% of m e a n  by Me thod  I). 
Figure  1 i l lustrates the var ia t ion  in appa ren t  digoxin bioavai labi l i ty  as a 
func t ion  of t ime. The  " t r u e "  bioavailabi l i t ies ,  based on dose-correc ted  
A U C  0-oo ratios, are shown above  the infinity signs at the far right of the two 
graphs.  These  " t r u e "  bioavailabi l i t ies ,  based on  A U C  0-oo 's  ob ta ined  by 
Me thod  I, are very similar  to those es t imated  by Me thod  IIC. This new 
in te rp re ta t ion  of the data  of W a g n e r  et al. (5) indicates  that  digoxin,  
admin i s te red  as an aqueous  solut ion oral ly in those studies,  was comple te ly  
absorbed.  This agrees with similar  es t imates  made  f rom 10-day ur ina ry  
excre t ion data  (3) and  disagrees with data  summar i zed  by G r e e n b l a t t  et  al. 
(18) and  with the or iginal  es t imates  of W a g n e r  et  al. (5), based on  appa ren t  
bioavailabil i t ies .  The  graphs in Fig. 1 i l lustrate how impossible  it is to 
compare  appa ren t  bioavai labi l i t ies  of different  invest igators  who sample  
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Fig. 1. Apparent bioavailabilities as a function of 
time for two subjects based on the digoxin plasma 
concentrations of Wagner et al. (5). Apparent 
bioavailabilities were calculated from the dose- 
corrected ratio of areas under the plasma 
concentration-time curves. The "true" 
bioavailabilities are given by the points above the 
infinity sign and are based on total areas esti- 
mated by Method [. Key: A, oral solution relative 
to 1-hr intravenous infusion; B, B & W (Lanoxin) 
tablet relative to 1-hr intravenous infusion; C, 
Fougera tablet relative to I-hr intravenous infu- 
sion. Top, subject 1; botton, subject 2. 
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Table II. Comparison of Results Based on Partial Areas with Those Based on Total Areas 
Obtained by Method I 
Apparent bioavailability of digoxin in the 
Fougera tablet relative to that in the B & W tablet 
Area utilized Subject 1 Subject 2 Average 
0-5hr 57.7 Decrease 41.3 Increase 49.5 
0-96 hr 48.5 [ with 60.7 I with 54.6 
0-oo 44.7 ~ time 69.4 ~ time 57.1 
blood for different times, such as 3, 4, 5, 6, 8, 12, 24, 48 and 96 hr (7-21). It 
also should be noted that in three out of four examples the " t rue"  bioavaila- 
bility estimates for the tablets were lower than the values estimated from 
A U C  0-96 hr data. Also, throughout  the 12-96 hr period, the trend lines 
rise for subject 1 (curves A and B) and subject 2 (curves A and C), but the 
trend line falls in the same period for subject 2 (curve B). It is also obvious 
from the figure that a 6-hr sampling scheme, as recommended by the Food 
and Drug Administration for digoxin (31), cannot provide " t rue"  bioavaila- 
bility estimates for digoxin. 
Table II compares results based on partial areas with those obtained by 
total areas, when the Fougera tablet is compared to the B & W tablet as a 
"standard."  For subject 1 there is a decrease with increase in time, and for 
subject 2 there is an increase with increase in time. Klink et al. (13) also 
reported data on the apparent  bioavailabilities of digoxin from the B & W 
tablet and a Towne-Paulsen tablet, relative to digoxin elixir. For the B & W 
tablet the values were 71%, 83%, 96%, and 106%, and for the Towne- 
Paulsen tablet they were 65%, 74%, 85%, and 101%, based on ratios of 
A U C  values to 5, 12, 24, and 48 hr, respectively. These results make 
questionable the conclusions of Greenblatt  et al. (15,18) and Lovering et al. 
(17) that areas under truncated plasma or serum concentra t ion- t ime curves 
are satisfactory to estimate digoxin bioavailability. 
Importance o| Blood Sampling Scheme 
Figure 2 shows simulated digoxin plasma concentrations for a "fast- 
release" (A) and a "slow-release" (B) digoxin formulation. Table III 
summarizes apparent  bioavailabilities as a function of time, estimated from 
AUCs obtained by trapezoidal rule from the data shown in Fig. 2. Care must 
be taken to read Table III correctly. The " t rue"  bioavailability is 97.4%. 
Values listed in rows 1 to 8 under "Apparen t  bioavailability" are those 
which would be estimated with the given sampling scheme and the areas 
under the truncated curves up to the last sampling time. Thus with the 3-hr 
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Fig. 2. Simulated digoxin plasma concentrations for "fast-release" and 
"slow-release" digoxin formulations. 
sampling scheme in row 1 one underestimates the "true" bioavailability by 
100 (97.4-84.3)/97.4 = 13.4%. With the 6-hr sampling scheme in row 2 one 
underestimates the "true" bioavailability by 14.7%. For this simulation the 
96-hr sampling schemes of rows 6-8 give AUC 0-96 hr estimates between 
99.3% and 99.8% of the "true" bioavailability, while Method IIC (last 
column of Table III) gives estimates from 100.1% to 100.4% of the "true" 
bioavailability. Values listed in the last row of Table III are those obtained 
with equations 23 and 25 of the Appendix. Discrepancies between the 
numbers when one reads vertically in the table--for example, comparing 
84.3 in row 1 with 76.9 in row 9--are caused by the sampling scheme's not 
truly defining the actual curves. This is a m i n i m u m  (not a maximum) test and 
does show that sampling schemes only up to 8 hr do introduce appreciable 
error in bioavailability estimates. As stated in the Introduction, Beveridge et 
al. (16) claimed that with real data areas under digoxin plasma concentra- 












































































































































































































































































































































































































































































































































































































































































































































Bioavailability Assessment 547 
Lovering et al. (17) stated: "The AUC ratios at t = 2T are, in most 
cases, within a few percentage points of the A U C  ratio at infinite time and 
experimentally indistinguishable from it." Here T is the time absorption was 
allowed to proceed in their simulations. In the present simulations the 
"fast-release" formulation had released 99% of the "drug" in 0.66 hr, 
hence we can consider 2T equal to 1.32 br; the "slow-release" formulation 
had released 99% of the "drug" in 1.735 hr, hence we can consider 2T equal 
to 3.5 hr. The actual apparent bioavailabilities were 76.9% and 80.4% at 3 
and 4hr, respectively, which are 20.5% and 17.4% from the "true" 
bioavailability of 97.4%. Hence the conclusions of Lover~ng et al. (17) with 
respect to the validity of use of truncated blood level curves should not be 
applied to digoxin. 
Estimation of A ~ Data of Juhl et  al.  (20) 
Juhl et al. (20) measured urinary excretion of digoxin in ten subjects 
over a 10-day period after oral administration of 0.5 mg digoxin (as B & W 
elixir, 0.05 mg/ml) alone, then again when the subjects had been adminis- 
tered sulfasalazine for 6 days. Individual subject data were kindly supplied 
to us by Dr. Juhl. Table IV lists the mean amounts of digoxin excreted to the 
various times, with their standard errors, both in micrograms and expressed 
as a percent of the means. In the last three columns of Table IV are given the 
apparent bioavailabilities in percent under the beading "Ratio of means z 
100," as well as the standard error (sz) of the ratio, and these expressed as a 
percentage of the mean ratio. The formula used for the SE of the mean ratios 
is shown in footnote b to Table IV. Since, usually, bioavailability estimates 
are made from a ratio of means, the variances of values from which both the 
numerator and denominator were obtained influence the variance of the 
ratio. The formula for the SR of the ratio given takes this into consideration; 
this formula does not appear to have been employed in bioavailability 
studies formerly, but should be employed in the future. 
Also listed in Table IV are the bioavailabilities, calculated from the 
ratios of mean A~  values, obtained by Methods I, IIA, IIB, and IIC, as well 
as the mean Aft  values with their standard errors. Method IIA, employing 
only 3-, 4-, and 5-day excretion data, gave rather poor estimates of A~, with 
a consequent low bioavailability estimate of 75.5% and a high value of 
12.3% for 100 (SE of ratio)/ratio. As with the former AUC,t data, Methods 
I and IIC, using 3-10 day excretion data, gave the same bioavailability 
estimate of 82.1%, with essentially the same standard errors, namely 5.64 
and 5.57. Method IIC, using only 3-6 day data, gave a similar estimate of 
82.3% for bioavailability, with a standard error of 5.04. In applying 
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Fig. 3. Plots of (A,)i vs. (A,)i+l -(A,) i  prepared 
from the data of Juhl et al. (20) for subjects 1 and 
2 given digoxin alone. The orthogonal least- 
squares lines, based on 3-10 day excretion of 
digoxin, have been extrapolated to show that the 
points based on l- and 2-day excretion lie above 
the extrapolated line, indicating that urinary 
excretion is not apparent first order until day 3. 
Key: A, subject 1, digoxin alone, intercept= 
A~=322~tg; B, subject 2, digoxin alone, 
intercept = A ~ = 297/zg. 
since there was evidence with many data sets that the Ae,t  data were not 
truly log linear until day 3. This is reflected in the larger standard errors for 
both mean amounts  excreted and apparent  bioavailabilities for days I and 2 
compared  to days 3 through 10 (Table IV). 
In applying Methods IIB and I IC  one should first plot (Ae)i vs. 
( A e ) i + l  - (Ae)i o r  (AUC)i VS. ( A U C ) i + I  - (AUC)i, as shown in Fig. 3. In our  
modification, data are plotted as shown, while Amidon et al. (27) plotted in 
the reverse manner ,  i.e., (Ae) i+l - (Ae) i  vs. (Ae)i. Plots prepared  f rom the 
data of Juhl et al. (20) for subjects 1 and 2 given digoxin alone are shown in 
Fig. 3. The orthogonal  least-squares lines (Method IIC), based on 3-10  day 
excretion, are drawn through the points, and then these lines are extrapo-  
lated. One can see that the points derived f rom 1- and 2-day excretion, at far 
right of the figure, lie above the extrapolated lines. Because of the increasing 
separation of the points on such a plot, the inclusion of the points based on 
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day 1 and 2 excretion in calculation of the orthogonal least-squares line 
would unduly influence the estimated value of the intercept, A ~; inclusion 
of such points leads to estimates of Ae ~ which are lower than the value of Ae 
at the last sampling time. Deviation of such points from the extrapolated 
line, based on later time points, strongly suggests that day 1 and 2 excretion 
data are not in the log-linear phase. This may be caused by the nonspecificity 
of the digoxin radioimmunoassay (22), more rapid excretion of some 
cross-reacting metabolites than digoxin, and thus a changing 
metabolite/unchanged drug ratio in urine with time, as formerly pointed out 
by Stoll and Wagner (32). Hence we chose to estimate Ae only from the 3-6 
and 3-10 day urinary excretion data. Similarly, with the data of Wagner et al. 
(5) such plots indicated that the plasma concentration and AUC,t  data from 
24 to 96 hr were in the log-linear phase but that the 12-hr data were not. The 
reason for the discrepancy between plasma concentration and urinary 
excretion data for digoxin with respect to the time when the log-linear phase 
commences is unknown at this time. 
The apparent bioavailability estimate of 82.2% from 1-day urinary 
excretion is essentially the same as the bioavailability estimate of 82.1% 
based on A ~  values obtained by Methods I (3-10 days) and IIC (3-10 days), 
but the standard error of 8.89% for 1-day excretion is higher than the values 
of 5.64% and 5.57% obtained using Methods I and IIC to obtain Ae ~. The 
greater variability of apparent bioavailability based on 1-day excretion than 
bioavailability based on estimates of A ~ with these data supports arguments 
made in the Theoretical section. 
Table V lists the individual subject/treatment values of Ae and appar- 
ent elimination rate constants, A1, obtained by Methods I and IIC and 
equation 18. The standard deviations of these two estimated parameters and 
the average absolute percent deviation and range of percent deviations of Ae 
from observed A~ obtained by Method I are also shown in the table. These 
standard deviations of the estimated parameters are very small relative to 
the estimates, and the percent deviations are very small compared to most 
other nonlinear least-squares fitting with which the senior author is familiar. 
This strongly supports obeyance of first-order kinetics in the 3-10 day 
period. The mean absolute deviation of A~'s  estimated by Methods I and 
IIC is only 1 tzg, and in five out of the 20 sets of data both methods gave the 
same estimate of A ~. Differences in the )t 1 values obtained by Methods I 
and IIC just reflect how sensitive such values are to change in asymptote (A 
value) used when applying equation 18. Frequently authors use the 
observed amount excreted to the end of their observation period (here 10 
days) as the asymptote, with consequent considerable error in estimated 
apparent elimination rate constant or elimination half-life. This was discus- 
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The Guggenheim method (1 d, 29) and the "rate method" (le) gave very 
poor estimates for A ff of 150 and 151, respectively, from the data of subject 
1 (digoxin plus sulfasalazine), compared to values of 256 and 253 obtained 
by Methods I and IIC, respectively. As a result, these methods were not 
evaluated further with respect to digoxin urinary excretion data. 
Table VI lists the mean apparent elimination rate constants, hi, the 
95% confidence intervals of h 1, and the corresponding apparent elimination 
half-lives, as well as the coefficients of variation of h 1, obtained by the 
estimation of A ~  by Methods I through IIC and then applying equation 18. 
Such a comparison is even more sensitive than a comparison of A ~  values 
(Tables IV and V). Data in Table V! show that the most elegant method, 
Method I, gave the smallest 95% C.I. for h i and the smallest coefficients of 
variation. The poorest method, Method IIA, gave the largest 95% C.I.'s of 
)tl and the largest coefficients of variation. Method IIB (3-10 days) gave 
95% C.I.'s and coefficients of variation just slightly different than those of 
Method I, with Method IIC (3-10 days) a close second. With just 3-6 day 
excretion, Methods IIB and IIC gave larger confidence intervals and coeffi- 
cients of variation, but the estimates themselves are quite good when 
compared to those obtained by Method I (3-10 days). Table VI clearly 
shows what is often attributed to intersubject variation is just the result of 
the method used to estimate apparent elimination rate constants and 
half-lives. From the A 1 values estimated by Method I, intersubject variation 
in apparent elimination half-life of digoxin is indicated by a mean nor- 
malized difference of 16.0%, with a range of 1.7-36%, when equation 19 is 
employed. 
Normalized difference (%) = I(h/2)a -(h/2)a+s[ x 100 (19) 
[(tl/z)a h- (h/z)a+s]/2 
In equation 19, (h/z)a is the half-life obtained with digoxin alone and 
(h/z)a+s is the half-life obtained when digoxin was administered after 
sulfasalazine. Of course, in this case, intersubject variation may be con- 
founded with a possible effect of sulfasalazine on the half-life of digoxin, but 
there was no real evidence of such an effect. 
A reevaluation (34) of the digoxin intravenous data of Koup et al. (14) 
gave a mean elimination half-life of 42.1 hr, with a range of 33.0-53.3 hr. 
The half-lives shown in Table VI, obtained from a different panel of subjects 
and from urinary excretion data obtained after oral administration, agree 
very well with those data. 
CONCLUSIONS 
1. Method IIC, requiring only a desk calculator, and Method I, 
requiring a digital computer, give extremely similar estimates of both 
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AUC 0 - ~  and A e ~, provided that there are at least four values of AUC or Ae 
in the terminal log-linear phase. Method IIC is preferred over Method liB, 
both on a statistical basis and on the basis of results obtained with real AUC 
data. Methods l ib  and IIC, based on the method proposed by Amidon et al. 
(27), but incorporating a least-squares extrapolation, are more accurate with 
real (noisy) data than Method IIA. 
2. The plots of (Ae)i vs. (A~)/+I -(Ae)i  (see Fig. 3) or similar plots of 
(AUC)i vs. (AUC)i+~ - (AUC)/are often a more sensitive indicator of when 
the log-linear phase begins than classical semilogarithmic plots. 
3. Because of 1 and 2 above it may be wise for investigators seriously 
to consider writing protocols which provide for the taking of four equally 
spaced blood and urine samples in the log-linear phase after administration 
of single doses of not only digoxin but also any drug where the purpose of the 
study is to gather bioavailability or pharmacokirietic information. There 
must, of course, also be enough samples drawn prior to the commencement 
of the log-linear phase to describe adequately the plasma concentration- 
time curve and/or the amount excreted-time curve. 
4. A 0-6 hr blood sampling scheme for digoxin will yield a significant 
underestimate of relative bioavailability when "slow-release" and "fast- 
release" digoxin preparations are compared after oral administration. 
5. Digoxin administered orally as an aqueous solution is most proba- 
bly more bioavailable than formerly reported. The senior author formerly 
reported (5) about 80% absorption from the aqueous solution (relative 
to 1-hr intravenous infusion) based on comparison of dose-corrected 
AUC 0-96 hr's. Reevaluation of these data in this report indicates 100% 
absorption. Hence in estimating absolute bioavailabilities of oral dosage 
form of digoxin (i.e., intravenous route as the standard) the appropriate 
answer appears to be obtained only when one estimates AUC 0-o0's after 
both routes. 
6. The formerly reported greater interindividual variability of AUC 
data compared with Ae data for digoxin is explained in that the AUCs but 
not the A~'s involve the renal clearance. 
7. Preliminary data suggest that the intraindividual variability of the 
renal clearance of digoxin is very similar in magnitude to the interindividual 
variability. 
8. When bioavailabilities are estimated from the ratio of mean dose- 
corrected AUCs or A~'s, the standard error calculated by the formula in 
footnote b of Table IV may be used as a measure of the error of the 
bioavailability estimate. 
9. The magnitudes and variability of apparent elimination rate con- 
stants and half-lives of digoxin (and presumably other drugs), estimated 
from urinary excretion data by the or- method, depend on the value used for 
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the asymptotic amount excreted. Method IIC provides a simple procedure 
to estimate the appropriate A ~  for application of the or- method. 
10. As far as the relative bioavailability estimate is concerned, follow- 
ing oral administration of digoxin there appears to be no particular advan- 
tage in collecting urine beyond 24 hr. However, the standard error of the 
bioavailability estimate does decrease somewhat as the urinary collection 
period is extended up to 10 days. 
APPENDIX 
Orthogonai Least Squares (28) 
The slope and intercept of the orthogonal least-squares lines when 
Method IIC was applied in this study were obtained with 
2 --2 2 2 +  2 Slope = [(s~ - Sx) + ~/(s r - sx) 4(sxy) ] /2&y (20) 
Intercept = y = (slope) Y (21) 
where 
2 sx = Z x 2 - ( ~ , x ) 2 / N  2 s y = E y 2  (Xy)Z/N 
= E x / N  ~ = s y / N .  
sxy = X x y  - X x X y / N  
Simulation to Show Importance of Blood Sampling Scheme 
Plasma concentrations, Cp, for the "fast-release" formulation, A, were 
given by 
(~p= 0.4 e - ~ 1 7 6 1 7 6  2 . 0  e - ~ 1 7 6  + 1 e - 1 0 ( t - 0 . 2 )  3.4 e-l~176 
(22) 
The corresponding AUCs were given by 
A U C  = 30.2342-[27.3973 e-~176176 3.0769 e-~176 
+ 0.1 e-~~162 _ 0.34 e-1~176 (23) 
Plasma concentrations for the "slow-release" formulation, B, were 
given by 
Cp = 0.4 e-0.0146(t-0.2)]_ 2.0 e-0.65(t-0,2) + 1 e-lo(t-e.2)_ 3.4 e-3(t-~ (24) 
The corresponding AUCs were given by 
0 0146(t 0 2) 0 65(t 0 2) AUC = 29.4409-[27.3973 e-  " - " +3.0769 e-  " - 
+ 0.1 e -l~176 - 1.1333 e -3(t-~ (25) 
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